在克罗地亚的全科医生中处方抗糖尿病药物 - - 一项现实生活的跨部门研究
Tomislav Kurevija1,2, Ema Schönberger1,3, Matea Matić Ličanin1
1Faculty of Medicine, J.J. Strossmayer University of Osijek, 31000 Osijek, Croatia.
Biomedicines
|June 26, 2025
概括
克罗地亚的全科医生 (GPs) 为大多数2型糖尿病 (T2D) 患者提供护理,但血糖控制和心血管风险管理仍然不理想. 一般医生正在慢慢地采用对T2D的新治疗指南和药物.
科学领域:
- 内分泌学和新陈代谢学
- 一般医疗和初级保健服务.
- 心血管医学 心血管医学
背景情况:
- 最近的T2D治疗进展侧重于疾病进展和心血管 (CV) 并发症的预防.
- 尽管取得了进展,但T2D患者在全球范围内表现出低于最佳的血糖控制和心血管风险管理.
- 一般医生 (GPs) 在T2D管理中发挥着至关重要的作用.
研究的目的:
- 评估克罗地亚全科医生对抗糖尿病药物的处方做法.
- 评估全科医生对当前T2D治疗指南的理解和应用.
- 确定克罗地亚的一般医生对T2D管理的模式.
主要方法:
- 一个匿名的,自行设计的在线调查被分发给克罗地亚各地的全科医生.
- 受访者报告了基于电子健康记录的T2D患者数量和处方药物.
- 没有对GP特征的限制.
主要成果:
- 一般医生管理约59%的T2D患者,只有47%的患者达到目标HbA1c水平.
- 虽然大多数全科医生每年都会审查T2D治疗,但只有47.6%的人完全理解EASD/ADA指南.
- 58.3%的人采用HbA1c和CV风险控制的双重原则;SGLT2抑制剂在CV并发症中很常见.
结论:
- 克罗地亚的全科医生倾向于使用较旧的T2D治疗方法.
- 新的治疗方案和T2D的指导方针正在逐渐被采用.
- 在全科医生中,对T2D的新型,更有效的药物的处方正在增加.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Diabetes: Management and Pharmacotherapy
410
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
410
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K


